Clinical Manifestations Associated with Overweight/Obesity in Puerto Ricans with Fibromyalgia Syndrome

Table 4

Current and past pharmacological and nonpharmacological therapies in nonoverweight/obese and overweight/obese fibromyalgia patients.

	⁢Current therapy			⁢Past therapy
	Nonoverweight/obese	Overweight/obese	value	Nonoverweight/obese	Overweight/obese	value
Therapy	BMI ≤ 24.9	BMI ≥ 25		BMI ≤ 24.9	BMI ≥ 25
	()	()		()	()
	%	%		%	%
Tricyclic antidepressants	5.7	18.4	0.055	37.1	48.6	0.236
Selective serotonin reuptake inhibitors	28.6	22.0	0.427	57.1	65.1	0.394
Serotonin-norepinephrine reuptake inhibitor	34.3	44.0	0.309	57.1	66.1	0.340
Anticonvulsants	31.4	53.2	0.025	65.7	72.5	0.444
Benzodiazepines	14.3	25.7	0.163	22.9	42.2	0.040
Muscle relaxants	28.6	28.4	0.988	68.6	70.6	0.816
Nonselective nonsteroidal anti-inflammatory drugs	28.6	31.2	0.770	85.7	80.7	0.505
Cyclooxygenase-2 inhibitor	14.3	11.9	0.713	54.3	51.4	0.764
Opioids	0.0	3.7	0.324	5.7	15.6	0.108
Psychotherapy	22.9	32.1	0.298	45.7	48.6	0.764
Physical therapy	2.9	9.2	0.201	71.4	69.7	0.514
Acupuncture	2.9	0.9	0.428	20.0	13.8	0.261
Chiropractic therapy	2.9	0.9	0.428	20.0	11.0	0.141